

Advertisement

For Healthcare Professionals only

Prescribing Information

References



JACC

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Journal of the American College of Cardiology

Volume 74, Issue 5, August 2019

DOI: 10.1016/j.jacc.2019.05.064

PDF Article

Download

ORIGINAL INVESTIGATION

Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction


Awais Malik, Ravi Masson, Steven Singh, Wen-Chih Wu, Milton Packer, Bertram Pitt, Finn Waagstein, Charity J. Morgan, Richard M. Allman, Gregg C. Fonarow and Ali Ahmed

This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article.

Add to Cart (\$35)

Author + information

Central Illustration



[Download figure](#) | [Open in new tab](#) | [Download powerpoint](#)

Abstract

Background The deleterious effects of discontinuation of digoxin on outcomes in ambulatory patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) receiving angiotensin-converting enzyme inhibitors are well-documented.

Objectives The authors sought to determine the relationship between digoxin discontinuation and outcomes in hospitalized patients with HFrEF receiving more contemporary guideline-directed medical therapies including beta-blockers and mineralocorticoid receptor antagonists.

Methods Of the 11,900 hospitalized patients with HFrEF (EF \leq 45%) in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 3,499 received pre-admission digoxin, which was discontinued in 721 patients. Using propensity scores for digoxin discontinuation, estimated for each of the 3,499 patients, a matched cohort of 698 pairs of patients, balanced on 50 baseline characteristics (mean age 76 years; mean EF 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled.

Results Four-year post-discharge, digoxin discontinuation was associated with significantly higher risks of HF readmission (hazard ratio [HR]: 1.21; 95% confidence interval [CI]: 1.05 to 1.39; p = 0.007), all-cause readmission (HR: 1.16; 95% CI: 1.04 to 1.31; p = 0.010), and the combined endpoint of HF readmission or all-cause mortality (HR: 1.20; 95% CI: 1.07 to 1.34; p = 0.002), but not all-cause mortality (HR: 1.09; 95% CI: 0.97 to 1.24; p = 0.163). Discontinuation of digoxin was associated with a significantly higher risk of all 4 outcomes at 6 months and 1 year post-discharge. At 30 days, digoxin discontinuation was associated with higher risks of all-cause mortality (HR: 1.80; 95% CI: 1.26 to 2.57; p = 0.001) and the combined endpoint (HR: 1.36; 95% CI: 1.09 to 1.71; p = 0.007), but not of HF readmission (HR: 1.19; 95% CI: 0.90 to 1.59; p = 0.226) or all-cause readmission (HR: 1.03; 95% CI: 0.84 to 1.26; p = 0.778).

Conclusions Among hospitalized older patients with HFrEF on more contemporary guideline-directed medical therapies, discontinuation of pre-admission digoxin therapy was associated with poor outcomes.

Key Words

digoxin discontinuation heart failure mortality readmission reduced ejection fraction

Footnotes

The content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs. Dr. Ahmed was supported in part by the National Institutes of Health through grants R01-HL085561, R01-HL085561-S, and R01-HL097047 from the National Heart, Lung, and Blood Institute. The OPTIMIZE-HF registry was sponsored by GlaxoSmithKline, but played no role in the design, conduct, analyses, or interpretation of the current study. Dr. Packer has served as a consultant for Abbvie, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Cardioentis, Daiichi-Sankyo, Gilead, NovoNordisk, Pfizer, Relypsa, Sanofi, and Theravance. Dr. Pitt has been a consultant to Bayer, Sanofi, AstraZeneca, KBP Pharmaceuticals, scPharmaceuticals, Sarfez, Relypsa/Vifor, and Cereno Scientific; has stock options in KBP Pharmaceuticals, Relypsda, and Sarfez; and holds U.S. patent # 9931412 for site-specific delivery of eplerenone to the myocardium. Dr. Fonarow has been a consultant to Abbott, Amgen, Bayer, Janssen, Medtronic, and Novartis; has received research funding from Novartis; and was the principal investigator of the OPTIMIZE-HF registry. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.


Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.


Received April 7, 2019.

Revision received May 23, 2019.

Accepted May 28, 2019.

[View Full Text](#)

 This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click [Login](#) or the [Subscribe](#) link (top menu above) to access this article.

 [Add to Cart \(\\$35\)](#)

[Login](#)


[Previous](#)


[Next](#)

[Back to top](#)

Toolbox

 [Print PDF](#)

 [Email](#)

 [Share](#)

 [\(X\) Citation](#)

 [Permissions](#)

 [Metrics](#)



 [Add to Cart \(\\$35\) or Find in Other Sources](#)

Podcast

[Subscribe to Podcast](#)

[Download MP3](#)

Advertisement



The advertisement features a dark blue header with the 'practice UPDATE' logo on the left and the text 'MEMBERS GET FREE ACCESS TO:' on the right. Below the header is a dark grey area containing a white icon of a stack of papers on the left and the text 'Weekly scans of the premier journals in your specialty.' on the right. At the bottom is an orange bar with the text 'CLICK HERE TO JOIN' in white.

Similar Articles

[Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](#)
Cherinne Arundel, Ali Ahmed, et al.

[Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry](#)
Stephen J. Greene, Gregg C. Fonarow, et al.

[Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction](#)
Stephen J. Greene, Javed Butler, et al.

We recommend

[Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction](#)

Phillip H. Lam et al., *Journal of the American College of Cardiology*, 2017

[Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure](#)
Gianluigi Savarese et al., *JACC: Heart Failure*, 2019

[Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction](#)

Michael M. Givertz et al., *Journal of the American College of Cardiology*, 2017

[Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](#)
Cherinne Arundel et al., *Journal of the American College of Cardiology*, 2019

[Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](#)

PracticeUpdate, 2019

[Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction](#)

PracticeUpdate, 2017

[84 The prognostic significance of neutrophil to lymphocyte ratio in patients with heart failure with reduced and preserved ejection fraction](#)

Fraser Curran et al., *Heart*, 2019

Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction
Kyung-Kuk Hwang et al., Heart, 2018

Powered by **TREND MD**

Advertisement



JACC THE RHYTHM DISORDERS ARTICLE COLLECTION
BROWSE ARTICLES *new*
Educational Resources for Cardiovascular Specialists

JACC

Home
Topics
CME/MOC/ECME
Author Instructions
Submit Your Manuscript
JACC Journals Best of 2018



JACC Journals

JACC
JACC: Basic to Translational Science
JACC: CardioOncology
JACC: Cardiovascular Imaging
JACC: Cardiovascular Interventions
JACC: Case Reports
JACC: Clinical Electrophysiology
JACC: Heart Failure

General Information

About the Journals
Subscribe
eTable of Content Alerts
Reprints/Permissions
Operating Policies
Contact Us
Help
Privacy Policy
Registered User Agreement
Terms of Service
Cookie Policy

American College of Cardiology

[ACC.org](#)

[Image and Slide Gallery](#)

[CardioSmart](#)

[Cardiology Career Network](#)

[Cardiology](#)

[Cardiology: Interventions](#)

© 2019 JACC: Journal of the American College of Cardiology